Lars Ny

4.8k total citations
114 papers, 3.0k citations indexed

About

Lars Ny is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Lars Ny has authored 114 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 46 papers in Oncology and 27 papers in Immunology. Recurrent topics in Lars Ny's work include Immunotherapy and Immune Responses (27 papers), Cancer Immunotherapy and Biomarkers (26 papers) and CAR-T cell therapy research (21 papers). Lars Ny is often cited by papers focused on Immunotherapy and Immune Responses (27 papers), Cancer Immunotherapy and Biomarkers (26 papers) and CAR-T cell therapy research (21 papers). Lars Ny collaborates with scholars based in Sweden, Australia and Denmark. Lars Ny's co-authors include Lars Grundemar, Jonas A. Nilsson, Karl‐Erik Andersson, Per Alm, Roger Olofsson Bagge, Erik Larsson, Henrik Jespersen, Nils Johan Fredriksson, Lisa M. Nilsson and Bengt Larsson and has published in prestigious journals such as Nature Communications, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Lars Ny

104 papers receiving 2.9k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Lars Ny 1.3k 776 462 397 343 114 3.0k
Shinji Kosugi 1.6k 1.2× 359 0.5× 240 0.5× 346 0.9× 422 1.2× 177 4.4k
Beata Kos‐Kudła 497 0.4× 2.6k 3.4× 139 0.3× 428 1.1× 361 1.1× 243 4.9k
Antonio Agostino Sinisi 639 0.5× 270 0.3× 103 0.2× 725 1.8× 128 0.4× 118 3.3k
Suh‐Hang Hank Juo 1.5k 1.2× 298 0.4× 363 0.8× 515 1.3× 230 0.7× 129 4.3k
Ryo Ogawa 1.4k 1.1× 382 0.5× 204 0.4× 1.2k 3.1× 485 1.4× 271 4.4k
Sergio Li Calzi 1.5k 1.1× 276 0.4× 213 0.5× 640 1.6× 295 0.9× 59 2.9k
Anna Lisa Giuliani 1.0k 0.8× 227 0.3× 677 1.5× 210 0.5× 260 0.8× 70 3.5k
Alessandro Pini 629 0.5× 161 0.2× 217 0.5× 266 0.7× 180 0.5× 76 1.8k
Shoji Kagami 1.8k 1.4× 230 0.3× 1.1k 2.4× 543 1.4× 589 1.7× 206 5.9k
Shigeaki Muto 1.8k 1.4× 222 0.3× 192 0.4× 724 1.8× 394 1.1× 210 4.0k

Countries citing papers authored by Lars Ny

Since Specialization
Citations

This map shows the geographic impact of Lars Ny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Ny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Ny more than expected).

Fields of papers citing papers by Lars Ny

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Ny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Ny. The network helps show where Lars Ny may publish in the future.

Co-authorship network of co-authors of Lars Ny

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Ny. A scholar is included among the top collaborators of Lars Ny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Ny. Lars Ny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Huibers, Anne, Andrew Wong, Mark C. Burgmans, et al.. (2025). Management of liver metastases from uveal melanoma. British journal of surgery. 112(8). 1 indexed citations
2.
Huibers, Anne, Christian U. Blank, Gustav Ullenhag, et al.. (2025). Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma – A Swedish retrospective real-world study (NEO-MEL). European Journal of Cancer. 224. 115485–115485.
3.
Helgadóttir, Hildur, Göran Jönsson, Sara A. Wickström, et al.. (2025). SWE-NEO: Swedish NeoAdjuvant Trial Comparing anti-PD-1 Monotherapy to Combined anti-CTLA-4/anti-PD-1 blockade in Resectable Stage III Melanoma. 3. 100639–100639.
4.
All‐Eriksson, Charlotta, Christian Cahlin, Nils Elander, et al.. (2024). Long-term overall survival after isolated liver perfusion with melphalan in patients with isolated liver metastases of uveal melanoma (SCANDIUM trial).. Journal of Clinical Oncology. 42(16_suppl). 9532–9532.
5.
Helgadóttir, Hafdís T., et al.. (2024). 1079MO Survival before and after the introduction of adjuvant treatment in stage III melanoma: A nationwide registry-based study. Annals of Oncology. 35. S715–S716. 3 indexed citations
6.
Bagge, Roger Olofsson, Ana Carneiro, Hafdís T. Helgadóttir, et al.. (2024). A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial). ESMO Open. 9(7). 103623–103623. 4 indexed citations
7.
Bagge, Roger Olofsson, Charlotta All‐Eriksson, Christian Cahlin, et al.. (2023). Survival after isolated hepatic perfusion as a treatment for uveal melanoma liver metastases: Results from a randomized controlled trial (the SCANDIUM trial).. Journal of Clinical Oncology. 41(17_suppl). LBA9512–LBA9512. 1 indexed citations
8.
Karlsson, Joakim, Vasu R. Sah, Roger Olofsson Bagge, et al.. (2023). Patient-derived xenografts and single-cell sequencing identifies three subtypes of tumor-reactive lymphocytes in uveal melanoma metastases. eLife. 12. 2 indexed citations
9.
Helgadóttir, Hildur, et al.. (2023). Survival after introduction of adjuvant treatment in stage III melanoma: a nationwide registry-based study. JNCI Journal of the National Cancer Institute. 115(9). 1077–1084. 15 indexed citations
10.
Bagge, Roger Olofsson, Charlotta All‐Eriksson, Christian Cahlin, et al.. (2023). Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). Journal of Clinical Oncology. 41(16). 3042–3050. 33 indexed citations
11.
Isaksson, Karolin, Christian Ingvar, Marc Moncrieff, et al.. (2023). Prognostic Significance of Sentinel Lymph Node Status in Thick Primary Melanomas (> 4 mm). Annals of Surgical Oncology. 30(13). 8026–8033.
12.
Pinato, David J., Ruth Plummer, Martin Gutierrez, et al.. (2022). 622 A phase 1 study exploring the safety and tolerability of the small-molecule PD-L1 inhibitor, INCB099318, in patients with select advanced solid tumors. Regular and Young Investigator Award Abstracts. A654–A654. 3 indexed citations
13.
Ekstrand, Matias, Per Fogelstrand, Kristell Le Gal, et al.. (2021). Intussusceptive Angiogenesis in Human Metastatic Malignant Melanoma. American Journal Of Pathology. 191(11). 2023–2038. 16 indexed citations
14.
Sah, Vasu R., Joakim Karlsson, Henrik Jespersen, et al.. (2021). Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma. Melanoma Research. 32(4). 241–248. 15 indexed citations
15.
Ny, Lars, Christer Jensen, Henrik Jespersen, et al.. (2021). Early rise in brain damage markers and high ICOS expression in CD4+ and CD8+ T cells during checkpoint inhibitor-induced encephalomyelitis. Journal for ImmunoTherapy of Cancer. 9(7). e002732–e002732. 17 indexed citations
16.
Jespersen, Henrik, Roger Olofsson Bagge, Gustav Ullenhag, et al.. (2019). Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study. BMC Cancer. 19(1). 415–415. 52 indexed citations
17.
Lindberg, Mattias F., Henrik Jespersen, Samuel Alsén, et al.. (2019). HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy–Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Cancer Research. 79(5). 899–904. 89 indexed citations
18.
Isaksson, Karolin, et al.. (2019). A Population-Based Comparison of the AJCC 7th and AJCC 8th Editions for Patients Diagnosed with Stage III Cutaneous Malignant Melanoma in Sweden. Annals of Surgical Oncology. 26(9). 2839–2845. 11 indexed citations
19.
Muralidharan, Somsundar Veppil, Berglind O. Einarsdottir, Joydeep Bhadury, et al.. (2017). BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. Cell Death and Disease. 8(8). e2982–e2982. 15 indexed citations
20.
Wallerstedt, Susanna M., et al.. (2009). Risk of clinically relevant bleeding in warfarin‐treated patients—influence of SSRI treatment. Pharmacoepidemiology and Drug Safety. 18(5). 412–416. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shinji Kosugi Breakdown of academic impact, for papers by Beata Kos‐Kudła Breakdown of academic impact, for papers by Antonio Agostino Sinisi Breakdown of academic impact, for papers by Suh‐Hang Hank Juo Breakdown of academic impact, for papers by Ryo Ogawa Breakdown of academic impact, for papers by Sergio Li Calzi Breakdown of academic impact, for papers by Anna Lisa Giuliani Breakdown of academic impact, for papers by Alessandro Pini Breakdown of academic impact, for papers by Shoji Kagami Breakdown of academic impact, for papers by Shigeaki Muto
Rankless by CCL
2026